Related Experiment Videos
Random population-wide genetic damage induced in replicating cells treated with methotrexate
1Department of Molecular and Cell Biology, University of California, Berkeley 94720-3206, USA.
Mutation Research
|July 4, 1998
Summary
Low-dose methotrexate (MTX) treatment causes lasting, heritable growth reductions in mouse cells. This cellular damage may explain late side effects from cancer therapies.
Area of Science:
- Cell Biology
- Genetics
- Pharmacology
Background:
- Methotrexate (MTX) is a chemotherapy drug used to treat various cancers and autoimmune diseases.
- Understanding the long-term cellular effects of MTX is crucial for managing treatment side effects.
Purpose of the Study:
- To investigate the heritable effects of low-lethality methotrexate treatment on NIH 3T3 mouse cell growth rates.
- To explore the potential mechanisms and implications of MTX-induced cellular damage.
Main Methods:
- NIH 3T3 mouse cells were treated with methotrexate (MTX) at low-lethality concentrations.
- Growth rates of surviving cells and their clones were measured over serial passages.
- Cellular responses were compared in different culture media (MCDB 402 vs. DMEM) to assess drug efficacy.
Main Results:
- MTX treatment resulted in heterogeneous, heritable reductions in cell growth rates.
- Reduced growth rates were observed in early passages before faster-growing cells dominated.
- Differences in MTX efficacy were noted between MCDB 402 and DMEM media due to folate-sparing components.
Conclusions:
- Heritable growth rate reduction in cells treated with MTX suggests underlying genetic or chromosomal damage.
- This cellular damage may contribute to late-occurring side effects observed in patients undergoing chemotherapy.
- Further research into clastogenic changes induced by MTX is warranted to understand long-term health implications.